Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells 7,949 Shares of Stock

Aduro BioTech Inc (NASDAQ:ADRO) insider Stephen T. Isaacs sold 7,949 shares of the business’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $7.95, for a total value of $63,194.55. Following the transaction, the insider now directly owns 213,695 shares in the company, valued at approximately $1,698,875.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Aduro BioTech Inc (ADRO) opened at $7.45 on Thursday. Aduro BioTech Inc has a one year low of $6.01 and a one year high of $14.05. The company has a market capitalization of $575.91 and a P/E ratio of -5.48.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business had revenue of $3.79 million for the quarter, compared to the consensus estimate of $4.04 million. During the same quarter in the prior year, the firm posted ($0.54) earnings per share. The business’s revenue was up .0% compared to the same quarter last year. equities analysts expect that Aduro BioTech Inc will post -1.28 EPS for the current year.

Several brokerages have recently commented on ADRO. BidaskClub downgraded Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 3rd. HC Wainwright set a $10.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research note on Tuesday, December 19th. Canaccord Genuity set a $30.00 target price on Aduro BioTech and gave the stock a “buy” rating in a research note on Thursday, December 14th. Oppenheimer reduced their target price on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, December 13th. Finally, William Blair reiterated an “outperform” rating on shares of Aduro BioTech in a research note on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $17.71.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc boosted its stake in Aduro BioTech by 11.2% in the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 1,043 shares during the period. Fox Run Management L.L.C. bought a new stake in Aduro BioTech in the 3rd quarter valued at $127,000. SG Americas Securities LLC bought a new stake in Aduro BioTech in the 3rd quarter valued at $167,000. Trexquant Investment LP bought a new stake in Aduro BioTech in the 3rd quarter valued at $175,000. Finally, Voya Investment Management LLC boosted its stake in Aduro BioTech by 15.3% in the 2nd quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 2,515 shares during the period. Institutional investors and hedge funds own 45.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells 7,949 Shares of Stock” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.com-unik.info/2018/01/11/insider-selling-aduro-biotech-inc-adro-insider-sells-7949-shares-of-stock.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

What are top analysts saying about Aduro BioTech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aduro BioTech and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit